Related references
Note: Only part of the references are listed.Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Vicky Makker et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers
Ashton C. Berger et al.
CANCER CELL (2018)
Chemoproteomics-Aided Medicinal Chemistry for the Discovery of EPHA2 Inhibitors
Stephanie Heinzlmeir et al.
CHEMMEDCHEM (2017)
Chemical Proteomics and Structural Biology Define EPHA2 Inhibition by Clinical Kinase Drugs
Stephanie Heinzlmeir et al.
ACS CHEMICAL BIOLOGY (2016)
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
Katherine R. Amato et al.
CANCER RESEARCH (2016)
Cross-talk between EphA2 and BRaf/CRaf Is a Key Determinant of Response to Dasatinib
Jie Huang et al.
CLINICAL CANCER RESEARCH (2014)
Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
Katherine R. Arnato et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
A pan-cancer proteomic perspective on The Cancer Genome Atlas
Rehan Akbani et al.
NATURE COMMUNICATIONS (2014)
High throughput kinase inhibitor screens reveal TRB3 and MAPK-ERK/TGFβ pathways as fundamental Notch regulators in breast cancer
Julia Izrailit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
NetWalker: a contextual network analysis tool for functional genomics
Kakajan Komurov et al.
BMC GENOMICS (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer
William M. Merritt et al.
CANCER BIOLOGY & THERAPY (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim
J. Konishi et al.
ONCOGENE (2010)
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
Bryan T. Hennessy et al.
Clinical Proteomics (2010)
EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
Hui Miao et al.
CANCER CELL (2009)
Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor
C. W. Menges et al.
ONCOGENE (2008)
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer
Charles N. Landen et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
EphA2 as a target for ovarian cancer therapy
CN Landen et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
A conditional feedback loop regulates Ras activity through EphA2
M Macrae et al.
CANCER CELL (2005)
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery
CN Landen et al.
CANCER RESEARCH (2005)
Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis
M Nakamoto et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2002)
Activation of EphA receptor tyrosine kinase inhibits the Ras/MAPK pathway
H Miao et al.
NATURE CELL BIOLOGY (2001)
Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphorylation
H Miao et al.
NATURE CELL BIOLOGY (2000)
Share Paper
